Emergent BioSolutions Inc (NYSE:EBS) announced on Wednesday that the US Food and Drug Administration (FDA) has granted approval to the company’s drug Anthrasil (Anthrax Immune Globulin Intravenous), also known as AIGIV, for the treatment of inhalational anthrax, when used in conjunction with suitable antibiotics.
Inhalational anthrax is a rare bacterial disease caused by inhaling Bacillus anthracis, the anthrax-causing bacteria. Once inside the body, the bacteria reproduce and generate toxins that can cause extensive and permanent tissue damage and eventually death. The symptoms usually appear weeks after th...
Also watch: Common Causes of Hip Pain